Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 9OTHER_GOV 1OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 1

Interventions

Capecitabine 9Bevacizumab 8tislelizumab 7Oxaliplatin 7Drug Therapy 7pembrolizumab 6Surgical Procedures, Operative 6Standard of Care 6Cisplatin 6Radiotherapy 5Laparoscopy 5Fluorouracil 5Docetaxel 5Carboplatin 5Radiosurgery 4Leucovorin 4Exercise 4Epirubicin 4Cyclophosphamide 4toripalimab 3pertuzumab 3durvalumab 3dalpiciclib 3atezolizumab 3anlotinib 3Saline Solution 3Rituximab 3Prednisone 3Population Groups 3Observation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × parsaclisib × 1 year × Clear all
NCT05083208 2025-12-02

PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma

Henan Cancer Hospital

Phase 1 Terminated
12 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡